×

Fibrocell Science to Report Third Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on November 7, 2014

EXTON, Pa., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report third quarter and the first nine months of 2014 financial and operating results on November 7, 2014. David Pernock, chairman and chief executive officer of Fibrocell Science, will host the conference call and webcast at 8:30 a.m. EST, November 7, 2014.

The conference call may be accessed by dialing 855-877-0343 for domestic callers and 678-509-8772 for international callers. Please specify to the operator that you would like to join the "Fibrocell Science Third Quarter 2014 Financial Results Call, conference ID#: 19362761." The conference call will be webcast live under the investor relations section of Fibrocell's website at www.fibrocellscience.com/investors/events-and-presentations/, and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. Fibrocell is also pursuing medical applications for azficel-T—the Company's proprietary autologous fibroblast technology—for restrictive burn scarring and vocal cord scarring. Both indications are currently in Phase II clinical trials. For additional information, visit www.fibrocellscience.com.

CONTACT: Investor Relations: Susan Noonan S.A. Noonan Communications, LLC (212) 966-3650 susan@sanoonan.comSource:Fibrocell Science, Inc.